Novartis expands Kymriah manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia – GlobeNewswire

October 30, 2020 02:15 ET | Source: Novartis International AG

Basel, October 30, 2020 Novartis today announced the receipt of marketing authorization from Japans Ministry of Health, Labor and Welfare (MHLW) for Foundation for Biomedical Research and Innovation at Kobe ("FBRI") to manufacture and supply commercial Kymriah (tisagenlecleucel) for patients in Japan. This approval makes FBRI the first and only approved commercial manufacturing site for CAR-T cell therapy in Asia.

Behind our efforts to reimagine medicine with CAR-T cell therapy lies a commitment to build a manufacturing network that brings treatment closer to patients, commented Steffen Lang, Global Head of Novartis Technical Operations. The expertise and infrastructure of FBRI, a world-leading manufacturing organization, allows us to bring CAR-T manufacturing to Asia. With the Japan MHLW commercial manufacturing approval, the recent capacity expansion in the US and our ongoing efforts to optimize and evolve our processes, we are well-positioned to deliver this potentially curative treatment option to more patients around the world.

Novartis has the largest geographical CAR-T cell therapy manufacturing network in the world, including seven CAR-T manufacturing facilities, across four continents. Commercial manufacturing for Kymriah now takes place at five sites globally including at the Morris Plains, New Jersey facility, where the US Food and Drug Administration (FDA) recently approved a further increase in manufacturing capacity.

Kymriah is the first-ever FDA-approved CAR-T cell therapy, and the first-ever CAR-T to be approved in two distinct indications. It is a one-time treatment designed to empower patients immune systems to fight their cancer. Kymriah is currently approved for the treatment of r/r pediatric and young adult (up to 25 years of age) acute lymphoblastic leukemia (ALL), and r/r adult diffuse large B-cell lymphoma (DLBCL)1. Kymriah, approved in both indications by the Japan MHLW in 2019, is currently the only CAR-T cell therapy approved in Asia. Clinical manufacturing began at FBRI in 2019 and will continue alongside commercial manufacturing.

Kymriah was developed in collaboration with the Perelman School of Medicine at the University of Pennsylvania, a strategic alliance between industry and academia, which was first-of-its-kind in CAR-T research and development.

About Novartis Commitment to Oncology Cell & Gene Novartis has a mission to reimagine medicine by bringing curative cell & gene therapies to patients worldwide. Novartis has a deep CAR-T pipeline and ongoing investment in manufacturing and supply chain process improvements. With active research underway to broaden the impact of cell and gene therapy in oncology, Novartis is going deeper in hematological malignancies, reaching patients with other cancer types and evaluating next-generation CAR-T cell therapies that focus on new targets and utilize new technologies.

Novartis was the first pharmaceutical company to significantly invest in pioneering CAR-T research and initiate global CAR-T trials. Kymriah, the first approved CAR-T cell therapy, developed in collaboration with the Perelman School of Medicine at the University of Pennsylvania, is the foundation of Novartis commitment to CAR-T cell therapy. Kymriah is currently approved for use in at least one indication in 26 countries and at more than 260 certified treatment centers, with the ambition for further expansion to help fulfill the ultimate goal of bringing CAR-T cell therapy to every patient in need.

The Novartis global CAR-T manufacturing footprint spans seven facilities, across four continents. This comprehensive, integrated footprint strengthens the flexibility, resilience and sustainability of the Novartis manufacturing and supply chain. Commercial and clinical trial manufacturing is now ongoing at Novartis-owned facilities in Stein, Switzerland, Les Ulis, France and Morris Plains, New Jersey, USA, as well as at the contract manufacturing sites at Fraunhofer-Institut for cell therapy and immunology (Fraunhofer-Institut fr Zelltherapie und Immunologie) facility in Leipzig, Germany, and now FBRI in Kobe, Japan. Manufacturing production at Cell Therapies in Australia and Cellular Biomedicine Group in China is forthcoming.

ImportantSafety information from the Kymriah SmPC

EU Name of the medicinal product:

Kymriah 1.2 x 106 6 x 108 cells dispersion for infusion

Important note: Before prescribing, consult full prescribing information.

Presentation: Cell dispersion for infusion in 1 or more bags for intravenous use (tisagenlecleucel).

Indications: Treatment of pediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse posttransplant or in second or later relapse. Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

Dosage and administration:

B-cell patients: For patients 50 kg and below: 0.2 to 5.0 x 106 CAR-positive viable T-cells/kg body weight. For patients above 50 kg: 0.1 to 2.5 x 108 CAR-positive viable T-cells (non-weight based).

DLBCL Patients: 0.6 to 6.0108 CAR-positive viable T-cells (non-weight based).

Pretreatment conditioning (lymphodepleting chemotherapy): Lymphodepleting chemotherapy is recommended to be administered before Kymriah infusion unless the white blood cell (WBC) count within one week prior to infusion is 1,000 cells/L. The availability of Kymriah must be confirmed prior to starting the lymphodepleting regimen.

Precautions before handling or administering Kymriah: Kymriah contains genetically modified human blood cells. Healthcare professionals handling Kymriah should therefore take appropriate precautions (wearing gloves and glasses) to avoid potential transmission of infectious diseases.

Preparation for infusion The timing of thaw of Kymriah and infusion should be coordinated. Once Kymriah has been thawed and is at room temperature (20C 25C), it should be infused within 30minutes to maintain maximum product viability, including any interruption during the infusion.

Administration Kymriah should be administered as an intravenous infusion through latexfree intravenous tubing without a leukocyte depleting filter, at approximately 10 to 20mL per minute by gravity flow. If the volume of Kymriah to be administered is 20mL, intravenous push may be used as an alternative method of administration.

All contents of the infusion bag(s) should be infused.

Clinical assessment prior to infusion: Kymriah treatment should be delayed in some patient groups at risk (see Special warnings and precautions for use).

Monitoring after infusion: Patients should be monitored daily for the first 10 days following infusion for signs and symptoms of potential cytokine release syndrome, neurological events and other toxicities. Physicians should consider hospitalisation for the first 10 days post infusion or at the first signs/symptoms of CRS and/or neurological events. After the first 10 days following the infusion, the patient should be monitored at the physicians discretion. Patients should be instructed to remain within proximity of a qualified clinical facility for at least 4 weeks following infusion.

Elderly (above 65 years of age): Safety and efficacy have not been established in B-cell patients. No dose adjustment is required in patients over 65 years of age in DLBCL patients.

Paediatric patients: No formal studies have been performed in paediatric patients with B-cell ALL below 3 years of age. The safety and efficacy of Kymriah in children and adolescents below 18 years of age have not yet been established in DLBCL. No data are available.

Patients seropositive for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV): There is no experience with manufacturing Kymriah for patients with a positive test for HIV, active HBV, or active HCV infection. Leukapheresis material from these patients will not be accepted for Kymriah manufacturing.

Contraindications: Hypersensitivity to the active substance or to any of the excipients of Kymriah. Contraindications of the lymphodepleting chemotherapy must be considered.

Warnings and precautions: Reasons to delay treatment: Due to the risks associated with Kymriah treatment, infusion should be delayed if a patient has any of the following conditions: Unresolved serious adverse reactions (especially pulmonary reactions, cardiac reactions or hypotension) from preceding chemotherapies, active uncontrolled infection, active graft versus host disease (GVHD), significant clinical worsening of leukaemia burden or rapid progression of lymphoma following lymphodepleting chemotherapy. Blood, organ, tissue and cell donation: Patients treated with Kymriah should not donate blood, organs, tissues or cells.

Active central nervous system (CNS) leukaemia or lymphoma: There is limited experience of use of Kymriah in patients with active CNS leukaemia and active CNS lymphoma. Therefore the risk/benefit of Kymriah has not been established in these populations. Risk of CRS: Occurred in almost all cases within 1 to 10 days post infusion with a median time to onset of 3 days and a median time to resolution of8 days. See full prescribing information for management algorithm of CRS. Risk of neurological events: Majority of events, in particular encephalopathy, confusional state or delirium, occurred within 8 weeks post infusion and were transient. The median time to onset of neurological events was 8 days in B-cell ALL and 6 days in DLBCL; the median time to resolution was 7 days for B-cell ALL and 13 days for DLBCL. Patients should be monitored for neurological events. Risk of infections: Delay start of therapy with Kymriah until active uncontrolled infections have resolved. As appropriate, administer prophylactic antibiotics and employ surveillance testing prior to and during treatment with Kymriah. Serious infections were observed in patients, some of which were life threatening or fatal. After Kymriah administration observe patient and ensure prompt management in case of signs of infection Risk of febrile neutropenia: Frequently observed after Kymriah infusion, may be concurrent with CRS. Appropriate management necessary. Risk of prolonged cytopenias: Appropriate management necessary. Prolonged cytopenia has been associated with increased risk of infections. Myeloid growth factors, particularly granulocyte macrophage colony stimulating factor (GM CSF), not recommended during the first 3 weeks after Kymriah infusion or until CRS has been resolved. Risk of secondary malignancies: Patients treated with Kymriah may develop secondary malignancies or recurrence of their cancer and should be monitored lifelong for secondary malignancies. Risk of hypogammaglobulinemia or agammaglobulinemia: Infection precautions, antibiotic prophylaxis and immunoglobulin replacement should be managed per age and standard guidelines. In patients with low immunoglobulin levels preemptive measures such as immunoglobulin replacement and rapid attention to signs and symptoms of infection should be implemented. Live vaccines: The safety of immunisation with live viral vaccines during or following Kymriah treatment was not studied. Vaccination with live virus vaccines is not recommended at least 6 weeks prior to the start of lymphodepleting chemotherapy, during Kymriah treatment, and until immune recovery following treatment with Kymriah. Risk of tumor lysis syndrome (TLS): Patients with elevated uric acid or high tumor burden should receive allopurinol or alternative prophylaxis prior to Kymriah infusion. Continued monitoring for TLS following Kymriah administration should also be performed. Concomitant disease: Patients with a history of active CNS disorder or inadequate renal, hepatic, pulmonary or cardiac function are likely to be more vulnerable to the consequences of the adverse reactions of Kymriah and require special attention. Prior stem cell transplantation: Kymriah infusion is not recommended within 4 months of undergoing an allogeneic stem cell transplant (SCT) because of potential risk of worsening GVHD. Leukapheresis for Kymriah manufacturing should be performed at least 12weeks after allogeneic SCT. Serological testing: There is currently no experience with manufacturing Kymriah for patients testing positive for HBV, HCV and HIV. Screening for HBV, HCV and HIV, must be performed before collection of cells for manufacturing. Hepatitis B virus (HBV) reactivation, can occur in patients treated with medicinal products directed against B cells and could result in fulminant hepatitis, hepatic failure and death. Prior treatment with anti CD19 therapy: There is limited experience with Kymriah in patients exposed to prior CD19 directed therapy. Kymriah is not recommended if the patient has relapsed with CD19 negative leukaemia after prior anti-CD19 therapy. Interference with serological testing: Due to limited and short spans of identical genetic information between the lentiviral vector used to create Kymriah and HIV, some commercial HIV nucleic acid tests (NAT) may give a false positive result. Sodium and potassium content: This medicinal product contains 24.3 to 121.5mg sodium per dose, equivalent to 1 to 6% of the WHO recommended maximum daily intake of 2g sodium for an adult. This medicinal product contains potassium, less than 1mmol (39mg) per dose, i.e. essentially potassium free. Content of dextran 40 and dimethyl sulfoxide (DMSO): Contains 11 mg dextran 40 and 82.5 mg dimethyl sulfoxide (DMSO) per mL. Each of these excipients are known to possibly cause anaphylactic reaction following parenteral administration. Patients not previously exposed to dextran and DMSO should be observed closely during the first minutes of the infusion period.

Interaction with other medicinal products and other forms of interaction

Live vaccines: The safety of immunisation with live viral vaccines during or following Kymriah treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during Kymriah treatment, and until immune recovery following treatment with Kymriah.

Fertility, pregnancy and lactation

Women of childbearing potential/Contraception in males and females: Pregnancy status for females of reproductive potential should be verified prior to starting treatment with Kymriah. Consider the need for effective contraception in patients who receive the lymphodepleting chemotherapy. There are insufficient exposure data to provide a recommendation concerning duration of contraception following treatment with Kymriah.

Pregnancy: There are no data from the use of Kymriah in pregnant women. It is not known whether Kymriah has the potential to be transferred to the foetus via the placenta and could cause foetal toxicity, including B cell lymphocytopenia. Kymriah is not recommended during pregnancy and in women of childbearing potential not using contraception. Pregnant women should be advised on the potential risks to the foetus. Pregnancy after Kymriah therapy should be discussed with the treating physician. Pregnant women who have received Kymriah may have hypogammaglobulinaemia. Assessment of immunoglobulin levels is indicated in newborns of mothers treated with Kymriah.

Breast feeding: It is unknown whether Kymriah cells are excreted in human milk, a risk to the breast fed infant cannot be excluded. Women who are breast feeding should be advised of the potential risk to the breast fed infant. Breast-feeding should be discussed with the treating physician.

Fertility: There are no data on the effect of Kymriah on fertility.

Effects on ability to drive and use machines Driving and engaging in hazardous activities in the 8 weeks following infusion should be refrained due to risks for altered or decreased consciousness or coordination.

Adverse drug reactions:

B-Cell ALL patients and DLBCL patients:

Very common (10%): Infections - pathogen unspecified, viral infections, bacterial infections, fungal infections, anaemia, haemorrhage, febrile neutropenia, neutropenia, thrombocytopenia, cytokine release syndrome, hypogammaglobulinaemia, decreased appetite, hypokalaemia, hypophosphataemia, hypomagnesaemia, hypocalcaemia, anxiety, delirium, sleep disorder, headache, encephalopathy, arrhythmia, hypotension, hypertension, cough, dyspnoea, hypoxia, diarrhoea, nausea, vomiting, constipation, abdominal pain, rash, arthralgia, acute kidney injury, pyrexia, fatigue, oedema, pain, chills, lymphocyte count decreased, white blood cell count decreased, haemoglobin decreased, neutrophil count decreased, platelet count decreased, aspartate aminotransferase increased.

Common (1 to 10%): Haemophagocytic lymphohistiocytosis, leukopenia, pancytopenia, coagulopathy, lymphopenia, infusion-related reactions, graft versus host disease, hypoalbuminaemia, hyperglycaemia, hyponatraemia, hyperuricaemia, fluid overload, hypercalcemia, tumor lysis syndrome, hyperkalaemia, hyperphosphataemia, hypernatraemia, hypermagnesaemia, dizziness, peripheral neuropathy, tremor, motor dysfunction, seizure, speech disorder, neuralgia, ataxia, visual impairment, cardiac failure, cardiac arrest, thrombosis, capillary leak syndrome, oropharyngeal pain, pulmonary oedema, nasal congestion, pleural effusion, tachypnea, acute respiratory distress syndrome, stomatitis, abdominal distension, dry mouth, ascites, hyperbilirubinaemia, pruritus, erythema, hyperhidrosis, night sweats, back pain, myalgia, muscolosceletal pain, influenza-like illness, asthenia, multiple organ dysfunction syndrome, alanine aminotransferase increased, blood bilirubin increased, weight decreased, serum ferritin increased, blood fibrinogen decreased, international normalized ratio increased, fibrin D dimer increased, activated partial thromboplastin time prolonged, blood alkaline phosphate increased, prothrombin time prolonged.

Uncommon: B-cell aplasia, ischaemic cerebral infarction, flushing, lung infiltration.

Packs and prices: Country-specific.

Legal classification: Country-specific.

Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as potential, can, will, plan, may, could, would, expect, anticipate, seek, look forward, believe, committed, investigational, pipeline, launch, or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AGs current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis Novartis is reimagining medicine to improve and extend peoples lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the worlds top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews For Novartis multimedia content, please visithttps://www.novartis.com/news/media-library For questions about the site or required registration, please contact media.relations@novartis.com

References

1.Kymriah (tisagenlecleucel) Summary of Product Characteristics (SmPC), 2018.

# # #

Novartis Media Relations E-mail: media.relations@novartis.com

Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com

Continue reading here:
Novartis expands Kymriah manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia - GlobeNewswire

Stem Cell Media Market Analysis highlights the Impact of covid-19 (2020-2028) | Thermo Fisher, STEMCELL Technologies, Merck Millipore, Lonza, GE…

Stem Cell Media Market forecast to 2028

The Global Stem Cell Media Market report provides information about the Global industry, including valuable facts and figures. This research study explores the Global Market in detail such as industry chain structures, raw material suppliers, with manufacturing The Stem Cell Media Sales market examines the primary segments of the scale of the market. This intelligent study provides historical data from 2015 alongside a forecast from 2020 to 2028.

This report contains a thorough analysis of the pre and post pandemic market scenarios. This report covers all the recent development and changes recorded during the COVID-19 outbreak.

Results of the recent scientific undertakings towards the development of new Stem Cell Media products have been studied. Nevertheless, the factors affecting the leading industry players to adopt synthetic sourcing of the market products have also been studied in this statistical surveying report. The conclusions provided in this report are of great value for the leading industry players. Every organization partaking in the global production of the Stem Cell Media market products have been mentioned in this report, in order to study the insights on cost-effective manufacturing methods, competitive landscape, and new avenues for applications.

Get Sample Report: https://grandviewreport.com/sample/76306

Top Key Players of the Market: Thermo Fisher, STEMCELL Technologies, Merck Millipore, Lonza, GE Healthcare, Miltenyi Biotec, Corning, CellGenix, Takara, PromoCell

Types covered in this report are: Pluripotent Stem Cell Culture, Hematopoietic Stem Cell Culture, Mesenchymal Stem Cell Culture

Applications covered in this report are: Scientific Research, Industrial Production

With the present market standards revealed, the market research report has also illustrated the latest strategic developments and patterns of the market players in an unbiased manner. The report serves as a presumptive business document that can help the purchasers in the global market plan their next courses towards the position of the markets future.

Check Discount on Stem Cell Media Market report @ https://grandviewreport.com/discount/76306

Regional Analysis For Stem Cell MediaMarket

North America(the United States, Canada, and Mexico) Europe(Germany, France, UK, Russia, and Italy) Asia-Pacific(China, Japan, Korea, India, and Southeast Asia) South America(Brazil, Argentina, Colombia, etc.) The Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

This report covers all the essential information required to understand the key developments in the Stem Cell Media market and growth trends of each segment and region. It also includes a basic overview and revenue and strategic analysis under the company profile section.

Why B2B Companies Worldwide Rely on us to Grow and Sustain Revenues:

This report provides:

Get Full Report @ https://grandviewreport.com/industry-growth/Stem-Cell-Media-Market-76306

In the end, the Stem Cell Media Market report includes investment come analysis and development trend analysis. The present and future opportunities of the fastest growing international industry segments are coated throughout this report. This report additionally presents product specification, manufacturing method, and product cost structure, and price structure.

Contact Us: Grand View Report (UK) +44-208-133-9198 (APAC) +91-73789-80300 Email : [emailprotected]

Go here to see the original:
Stem Cell Media Market Analysis highlights the Impact of covid-19 (2020-2028) | Thermo Fisher, STEMCELL Technologies, Merck Millipore, Lonza, GE...

New screening tool could turn up genes tied to developmental disorders – STAT

Scientists in Vienna have developed a new human tissue screening technique that has identified previously unknown genes involved in causing microcephaly, a rare genetic disorder, and that could one day be used to identify unknown genes tied to other conditions.

In a study published Thursday in Science, researchers screened lab-grown human brain tissues for 172 genes thought to be associated with microcephaly, a condition in which babies are born with smaller-than-normal brains and have severe mental impairments. The search revealed 25 new genes linked to this rare neurological condition, adding to the 27 already known genes tied to microcephaly. The researchers also uncovered the involvement of certain pathways that were previously unknown to be connected to the disease.

This is a proof of concept, said Jrgen Knoblich, a molecular biologist at the Austrian Academy of Sciences Institute of Molecular Biotechnology and co-author of the study. With our ability to query many diseased genes at the same time and ask which ones are relevant in a human tissue, we can now study other diseases and other organs.

advertisement

For decades scientists have relied on small animals as models to make sense of how a human brain develops. But it turns out that our brains are not blown-up versions of a rodent brain. Mice and rat brain surfaces, for instance, are smooth, unlike the shrivelled walnut look of a human brain, with its countless folds. Also, these rodents are born with a somewhat complete brain, in which most neurons are in place, although they continue to form new connections after birth. In a human child, on the other hand, there are a massive number of neurons that form and populate the cortex after birth.

There are some processes that happen in our brain and not in mice brains that are responsible for human brains becoming so big and powerful, Knoblich said. This generates a very big medical problem, which is how do we study processes that are only happening in humans.

advertisement

To address this problem, several scientists including Knoblich developed human brain organoids that are no bigger than a lentil, created from stem cells, and function just like a working human brain. With an interest in studying neurodevelopmental disorders like microcephaly, Knoblichs team used these miniature substitute brains to look for clues about the genes that may hamper brain development.

Typically, scientists conduct genetic screening by inactivating select genes one by one to understand their contribution to bodily functions. But screens of human genes are restricted to cells grown in petri dishes in two dimensions, in which cells dont interact very much.

Microcephaly is a tissue disease and we couldnt really study it in 2D, said Christopher Esk, a molecular biologist at the Austrian Academy of Sciences Institute of Molecular Biotechnology and co-lead author of the study.

So, the researchers developed a technique called CRISPR-Lineage Tracing at Cellular resolution in Heterogeneous Tissue, which uses the gene-editing technology to make cuts in DNA and knockout genes in combination with a barcoding technology that tracks parent stems and their progeny cells as the 3D brain organoid develops.

Using an organoid developed from cells of a microcephalus patient, they kept an eye out for mutations that gave rise to fewer cells and thus a small brain in comparison with a healthy one.

The researchers used CRISPR-LICHT to simultaneously screen 172 potential microcephaly causing gene candidates and found 25 to be involved.

Among them was a gene called Immediate Early Response 3 Interacting Protein 1 in the endoplasmic reticulum, which is the protein processing station within a cell. This protein processing is required to properly process other proteins, among them extracellular matrix proteins, which are in turn important for tissue integrity, and thus brain size, Esk said.

Kristen Brennand, a stem cell biologist at the Icahn School of Medicine at Mount Sinai in New York, who wasnt involved in the study, said she appreciated how the research captured this causal link. Clinical genetics can identify mutations in patients, but fall short of identifying causal mutations that definitively underlie disease risk, she said.

Going forward, Knoblich and his colleagues hope to use CRISPR-LICHT to screen many more genes that may be associated with other brain development disorders. Weve done it for microcephaly, and were already doing it for autism, he said. But the method can be applied to any type of organoid or any type of disease and any cell type.

Trending

It may be time to reset expectations on when

It may be time to reset expectations on when well get a Covid-19 vaccine

No news on Pfizers Covid-19 vaccine is good news

No news on Pfizers Covid-19 vaccine is good news and bad news

The Covid-19 Tracker

The Covid-19 Tracker

Recommended

Ashish Jha on Covid-19, pandemic fatigue, and when were

Ashish Jha on Covid-19, pandemic fatigue, and when were getting back to normal

Antibody drugs seem to work. But the virus is

Antibody drugs seem to work. But the virus is moving faster than we can make them

Is it safe to lick the ballot envelope? Public

Is it safe to lick the ballot envelope? Public health officials take on the new challenge

See the original post here:
New screening tool could turn up genes tied to developmental disorders - STAT

Regenerative Medicine Market Poised to Garner Maximum Revenues During 2025 – The Think Curiouser

Regenerative medicine is a part of translational research in the fields of molecular biology and tissue engineering. This type of medicine involves replacing and regenerating human cells, organs, and tissues with the help of specific processes. Doing this may involve a partial or complete reengineering of human cells so that they start to function normally.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1889

Regenerative medicine also involves the attempts to grow tissues and organs in a laboratory environment, wherein they can be put in a body that cannot heal a particular part. Such implants are mainly preferred to be derived from the patients own tissues and cells, particularly stem cells. Looking at the promising nature of stem cells to heal and regenerative various parts of the body, this field is certainly expected to see a bright future. Doing this can help avoid opting for organ donation, thus saving costs. Some healthcare centers might showcase a shortage of organ donations, and this is where tissues regenerated using patients own cells are highly helpful.

There are several source materials from which regeneration can be facilitated. Extracellular matrix materials are commonly used source substances all over the globe. They are mainly used for reconstructive surgery, chronic wound healing, and orthopedic surgeries. In recent times, these materials have also been used in heart surgeries, specifically aimed at repairing damaged portions.

Cells derived from the umbilical cord also have the potential to be used as source material for bringing about regeneration in a patient. A vast research has also been conducted in this context. Treatment of diabetes, organ failure, and other chronic diseases is highly possible by using cord blood cells. Apart from these cells, Whartons jelly and cord lining have also been shortlisted as possible sources for mesenchymal stem cells. Extensive research has conducted to study how these cells can be used to treat lung diseases, lung injury, leukemia, liver diseases, diabetes, and immunity-based disorders, among others.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1889<ype=S

Global Regenerative Medicine Market: Overview

The global market for regenerative medicine market is expected to grow at a significant pace throughout the forecast period. The rising preference of patients for personalized medicines and the advancements in technology are estimated to accelerate the growth of the global regenerative medicine market in the next few years. As a result, this market is likely to witness a healthy growth and attract a large number of players in the next few years. The development of novel regenerative medicine is estimated to benefit the key players and supplement the markets growth in the near future.

Global Regenerative Medicine Market: Key Trends

The rising prevalence of chronic diseases and the rising focus on cell therapy products are the key factors that are estimated to fuel the growth of the global regenerative medicine market in the next few years. In addition, the increasing funding by government bodies and development of new and innovative products are anticipated to supplement the growth of the overall market in the next few years.

On the flip side, the ethical challenges in the stem cell research are likely to restrict the growth of the global regenerative medicine market throughout the forecast period. In addition, the stringent regulatory rules and regulations are predicted to impact the approvals of new products, thus hampering the growth of the overall market in the near future.

Global Regenerative Medicine Market: Market Potential

The growing demand for organ transplantation across the globe is anticipated to boost the demand for regenerative medicines in the next few years. In addition, the rapid growth in the geriatric population and the significant rise in the global healthcare expenditure is predicted to encourage the growth of the market. The presence of a strong pipeline is likely to contribute towards the markets growth in the near future.

Global Regenerative Medicine Market: Regional Outlook

In the past few years, North America led the global regenerative medicine market and is likely to remain in the topmost position throughout the forecast period. This region is expected to account for a massive share of the global market, owing to the rising prevalence of cancer, cardiac diseases, and autoimmunity. In addition, the rising demand for regenerative medicines from the U.S. and the rising government funding are some of the other key aspects that are likely to fuel the growth of the North America market in the near future.

Furthermore, Asia Pacific is expected to register a substantial growth rate in the next few years. The high growth of this region can be attributed to the availability of funding for research and the development of research centers. In addition, the increasing contribution from India, China, and Japan is likely to supplement the growth of the market in the near future.

Global Regenerative Medicine Market: Competitive Analysis

The global market for regenerative medicines is extremely fragmented and competitive in nature, thanks to the presence of a large number of players operating in it. In order to gain a competitive edge in the global market, the key players in the market are focusing on technological developments and research and development activities. In addition, the rising number of mergers and acquisitions and collaborations is likely to benefit the prominent players in the market and encourage the overall growth in the next few years.

Some of the key players operating in the regenerative medicine market across the globe are Vericel Corporation, Japan Tissue Engineering Co., Ltd., Stryker Corporation, Acelity L.P. Inc. (KCI Licensing), Organogenesis Inc., Medtronic PLC, Cook Biotech Incorporated, Osiris Therapeutics, Inc., Integra Lifesciences Corporation, and Nuvasive, Inc. A large number of players are anticipated to enter the global market throughout the forecast period.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1889

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

See original here:
Regenerative Medicine Market Poised to Garner Maximum Revenues During 2025 - The Think Curiouser

High Response Rates Heighten Excitement With CAR T-Cell Therapy in Multiple Myeloma – OncLive

CAR T-cell therapy is poised to transform the treatment paradigm of relapsed/refractory multiple myeloma now that multiple products are exhibiting high and complete response (CR) rates, said Faiz Anwer, MD, who added that further research may improve safety, prolong responses, and provide insight into resistance mechanisms.

Due to the combination of specificity and cytotoxicity, we are seeing very high overall response rates [with CAR T-cell therapy], said Anwer. These response rates are variable, but in the range of 80% to 100%. The majority of these responses are very deep, [with most] patients achieving minimal residual disease [MRD] negativity. Achieving MRD negativity is the best outcome that we can expect from any therapy.

On September 22, 2020, the FDA granted a priority review designation to a biologics license application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) in patients with multiple myeloma who have received at least 2 previous therapies, including a proteasome inhibitor (PI), an immunomodulatory (IMiD) agent, and an anti-CD38 antibody.1

Data from the phase 2 KarMMa trial, which led to the BLA submission, showed that ide-cel induced a response in 73% of patients with heavily pretreated, relapsed/refractory disease. Moreover, the CR rate was 33% with the product.2

In an interview with OncLive during the 2020 Institutional Perspectives in Cancer webinar on hematologic malignancies, Anwer, an oncologist, physician-scientist, and stem cell transplant staff physician at the Taussig Cancer Center of Cleveland Clinic, a member of the Hematopoietic and Immune Cancer Biology Program at Case Comprehensive Cancer Center, and an associate professor in the Department of Medicine at the School of Medicine at Case Western Reserve University, discussed the growing role of CAR T-cell therapy in multiple myeloma and areas of unmet need.

Anwer: CAR T-cell therapy has some unique advantages compared with other treatments.CAR T-cell therapy has the advantage of targeted specificity, which we see with many monoclonal antibodies. At the same time, because [CAR T-cell therapy is] a cell-based, specifically T-cellbased, therapy, we see the cytotoxic advantage of T cells.

[Patients] receive a single infusion of CAR T cells. Many of these patients respond very quickly and maintain these responses for a long duration of time. Those longer lasting responses can [persist] for more than 1 year, and in many cases, more than a couple of years.

The benefit is that no maintenance therapy is required at this time. However, in the future, we can postulate that combination therapies will emerge, and a maintenance strategy will be introduced to improve the duration of response.

The CAR T-cell products [that are used in multiple myeloma] are safer compared with some of the other products that were used in the beginning in other diseases. In terms of safety, we are seeing less central nervous system [CNS] toxicity. The intensity of cytokine release syndrome [CRS], which is another major toxicity [associated with] CAR T-cell therapy, is actually less in multiple myeloma [than in other hematologic malignancies].

At this point, many targets are emerging aside from BCMA. We see a role for CD38 as a target as it is being explored with naked antibodies, such as daratumumab [Darzalex], in combination with antibody-drug conjugates.

In addition, GPRC5D is another target. CD19 has also been explored as another target. More excitement will come from dual targeting where either 2 different types of CAR T-cell therapies can be used, or 1 CAR T-cell product can be configured to achieve dual targeting of the myeloma cell.

We have more data from the phase 1 and 2 setting. That is where initial CAR T-cell therapy data were very exciting because [the studies] showed quicker, deeper responses with longer durations of response. They provided us with the initial insight into what type of adverse effects [AEs] we are going to face while using the CAR T-cell technology in multiple myeloma, as well as how to best manage [those AEs].

We will continue to see new products and new techniques emerge, which will likely [mitigate] some of these challenges. [Moreover], improved products and techniques will likely resolve some of these AEs that can be [severe].

In terms of responses for the products that are more advanced, [the data with] JNJ-4528/LCAR-B38M are exciting in terms of overall responses, which were reported in the range of 100%, with CRs approaching almost 70%. The MRD-negativity rate was also 100%.

At the same time, data from the KarMMa trial showed that ide-cel [induced] very high objective responses above 70%. The progression-free survival is measured in months and [CR rates] are also impressive with ide-cel.

We have learned through the treatment of other diseases, such as leukemia and lymphoma, that the challenges [that manifest with] CAR T-cell therapy are CRS and CNS toxicity. Were facing the same challenges in multiple myeloma.

Patients [treated with CAR T-cell therapy] are typically monitored very closely with daily assessments to [identify] these AEs. If [a patient] starts developing [signs of] CNS toxicity, such as confusion, seizures, fever, and low blood pressure, they are managed according to the defined protocol. Each individual center may have carved out their own unique approach to managing these toxicities, but typically, patients require close monitoring of fluid balance, antibiotics, and judicious use of steroids and tocilizumab [Actemra].

We need to have a comprehensive infection prophylaxis strategya vaccination strategyto prevent any long-term issues with infections. The therapy has to be integrated safety with the existing myeloma treatment [before patients receive] CAR T-cell therapy.

At this time, we can potentially count more than 50 open trials in the pipeline that will open for enrollment in the near future. The issues that we want to address include how to continue to make CAR T-cell therapy safe and effective, and to [prolong] responses.

Also, we want to look at the efficacy of repeat infusion and [identify] the optimal combination therapy with CAR T-cell therapy and other existing treatment. [Combinations] may be in the space of an IMiD, a PI, or a targeted antibody.

We also need to figure out how to overcome resistance, which ultimately [occurs] after an infusion while the CAR T cells are still in the body. What is the escape mechanism and how do we address it? Do we need to [implement] a dual-targeting approach? We may need to combine a multi-agent chemotherapy approach to improve upon the efficacy of the product and overcome the resistance.

At the same time, we need to continue to look at novel markers to improve responses and identify markers that we can potentially use to predict outcome. Is there a particular product for which a patient is going to respond better compared with another product? These individualized approaches where we can use unique CAR T-cell products for unique patients is where the future should be headed.

At this point, CAR T-cell therapy is being testing in heavily pretreated patient populations, but as we get more comfortable and see more data, we need to move CAR T up into the first- or second-relapse settings. In certain cases, it is absolutely justified to start testing CAR T-cell therapy in the frontline setting for patients who have high-risk multiple myeloma, patients who have primary resistance to frontline therapy, and patients who have plasma cell leukemias.

The major benefit of off-the-shelf CAR T-cell therapy products will be the time-to-treatment once we make a decision that the patient has relapsed/refractory disease [and requires CAR T-cell therapy].

At this time, we also face the challenge of T-cell collection failure in heavily pretreated patients who have cytopenias or have received heavy doses of radiation therapy to their bone marrow. In those cases, it may be difficult to collect T cells. Therefore, off-the-shelf products [would be advantageous in those cases.

One example [of an off-the-shelf product] is ALLO-715, which is in phase 1 testing at this time. We [may be able] to quickly infuse the cells to achieve effective disease control.

I encourage patients to participate in clinical trials to support new drug development. That is how we can continue to see further advancements in the field. That is how we have arrived to where we are now, and that is how we are going to [make even more advances] in the future. We need to continue to support research and drug development.

Read more from the original source:
High Response Rates Heighten Excitement With CAR T-Cell Therapy in Multiple Myeloma - OncLive

Cancer Stem Cells (CSCs) Market to Flourish with an Impressive Cagr During 2020-2027 – The Think Curiouser

Cancer Stem Cells (CSCs) Latest Research Report 2020 2026 covers a complete market structure across the world with the detailed industry analysis of major key factors. This report provides strategic recommendations consulted by the industrial experts including market forecasts, profit, supply, raw materials, labour cost, manufacturing expenses, proportion of manufacturing cost structure, latest market trends, demands and much more.

The progress in different sectors of the market that are highly dependent on market characteristics, industry chain, and market dynamics are also appearing in higher demand for the Cancer Stem Cells (CSCs) . Due to the increase of new technologies, the Cancer Stem Cells (CSCs) has been assisted in the development of the industry.

Request Sample Report @ https://chronicalmarketresearch.com/request-for-sample-report/25206

Key Players:

The Key manufacturers that are operating in the global Cancer Stem Cells (CSCs) market are:

Janssen

Qiagen

Advanced Cell Diagnostics

ApoCell

Biofluidica

Clearbridge Biomedics

CytoTrack

Celsee

Fluxion

Gilupi

Cynvenio

On-chip

YZY Bio

BioView

Creatv MicroTech

Fluidigm

Ikonisys

AdnaGen

IVDiagnostics

Miltenyi Biotec

Aviva Biosciences Corporation

ScreenCell

Silicon Biosystems

Competitive Landscape

The competition section of the Grapefruit report supplies exhaustive analysis of the competitive landscape in the business along with a product portfolio matrix. The section involves information on leading manufacturers which provide an insight into their financial performance, business highlights, and future plans. Furthermore, the Cancer Stem Cells (CSCs) report is classified according to their type, application, and regions by geography.

Request Discount About This Report @ https://chronicalmarketresearch.com/discount-request-on-report/25206

Continuous Cancer Stem Cells (CSCs) Research Market report will be beneficial for:

Global Cancer Stem Cells (CSCs) Region Coverage (Regional Output, Demand & Forecast by Countries etc.): North America (United States, Canada and Mexico) Europe (Germany, UK, France, Italy, Russia, Spain and Benelux) Asia Pacific(China, Japan, India, Southeast Asia and Australia), Latin America (Brazil, Argentina and Colombia) Middle East and Africa.

Following are the segments covered by the report are:

CellSearch

Others

By Application:

Breast Cancer Diagnosis and Treatment

Prostate Cancer Diagnosis and Treatment

Colorectal Cancer Diagnosis and Treatment

Lung Cancer Diagnosis and Treatment

Other Cancers Diagnosis and Treatment

Request For Customization About This Report @ https://chronicalmarketresearch.com/request-for-customization/25206

Reasons to Buy of Cancer Stem Cells (CSCs) Report

* Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.

* Examine potential investment and acquisition targets with this reports detailed insight into the companys strategic, business and operational performance.

* Understand and respond to your competitors business structure and strategies with detailed SWOT analysis. In this, the companys core strengths, weaknesses, opportunities, and threats are analyzed, providing you with an up to date objective view of the company.

* Identify potential customers and suppliers with this reports analysis of the companys business structure, operations, major products and services, and business strategy.

In the end, This report additionally presents product specification, producing method, and products cost structure. Production is separated by regions, technology and applications. The Cancer Stem Cells (CSCs) report includes investment come analysis, and development trend analysis. The key rising opportunities of the fastest growing international Grapefruit industry segments are coated throughout this report.

Contact Us

Chronical Market Research,

4004 W Lake Sammamish,

Pkway B9 Redmond,

WA 98052 United States.

Tel: +44 115 888 3028

Web: http://www.chronicalmarketresearch.com

About Us

At Chronical Market Research, we understand that the research we provide is only as good as the outcome it inspires. These reports are generated by well-renowned publishers on the basis of the data acquired from an extensive research and credible business statistics. Thats why we are proud to provide the widest range of research products, multilingual 24/7 customer support and dedicated custom research services to deliver the insights you need to achieve your goals. Take a look at few of our aspects that makes Chronical Market Research an asset to your business.

See original here:
Cancer Stem Cells (CSCs) Market to Flourish with an Impressive Cagr During 2020-2027 - The Think Curiouser

Novel Cell Sorting and Separation Industry Data Statistics Analysis by 2020-2025 – Eurowire

A new business intelligence report released by AMA Research with title Novel Cell Sorting and Separation Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020 is designed covering micro level of analysis by manufacturers and key business segments. The Novel Cell Sorting and Separation Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative detailing.

Some of the important players from a wide list of coverage used under bottom-up approach are NanoCellect Biomedical (United States),Innovative Biochips (United States),Fluidigm Corporation (United States), LumaCyte (United States),Union Biometrica (United States),LevitasBio (United States),RareCyte (United States),Cytonome (United States),Akadeum Life Sciences (United States),QIAGEN (Germany) Request a sample report @ https://www.advancemarketanalytics.com/sample-report/116923-global-novel-cell-sorting-and-separation-market

What is Novel Cell Sorting and Separation Market? Consequently, Novel Cell Sorting and Separation techniques have captured the interest of several stakeholders in the biopharmaceutical industry. It is also worth highlighting that stakeholders in this domain have received significant support from both private and public investors.Novel cell sorting and separation is important for the successful purification and isolation of blood cells, stem cells, and specific tissue cells. Cell separation through membrane filtration was recently reported by several researcher. It is Specifically, helpful in situations, such as the ongoing COVID-19 pandemic, healthcare organizations require precise cell analysis kits for timely detection of infections. Increasing outburst of covid-19 is one of the key driving factor of growth.

Market Segmentation & Scope

Study by Type (Cancer Cell, Immune Cells, Microbial Cell, Red Blood Cell/Platelet, Stem Cell, Others), Application (Academic Institutes, Clinical Testing Labs, Hospitals, Commercial Organizations, Others), Cell sorting technology (Buoyancy-activated, Magnetophoretics, Microfluidics, Optoelectronics, Other advanced technologies), Cell Separation Methods (Physicochemical, Affinity-based methods, Biophysical-based methods, Others), Size of cell (< 5 m, 5-10 m, 10-15 m, 15-25 m, > 25 m), Type of Offering (Cell sorters, Consumables and isolation kits), End User (Cell Research, Biomedical Diagnosis, Other)

Avail 10-25% Discount on various license type on immediate purchase @ https://www.advancemarketanalytics.com/request-discount/116923-global-novel-cell-sorting-and-separation-market

Market Influencing Trends: Emergence of Technological advancement Novel Cell Sorting and Separation

Growth Drivers Growing Adoption of Novel Cell Sorting and Separation Techniques in Research and Academia

Rising Global Incidence and Prevalence of Hiv/Aids and Cancer

Increasing Number of Research Projects Through Industry-Academia Collaborations to Drive Market Growth

Challenges that Market May Face: Lack of Well-Trained and Skilled Professionals

Check Complete Table of Content @ https://www.advancemarketanalytics.com/reports/116923-global-novel-cell-sorting-and-separation-market

Country level Break-up includes: North America (United States, Canada and Mexico) Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others) Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

The study is a perfect mix of qualitative and quantitative information and to get better understanding of how stats related to market sizing and share relates, the study is started with market overview and further detailed commentary is highlighted on changing market dynamics that includes Influencing trends by regions, Growth Drivers, open opportunities and gaps and roadblocks or restraints and challenges that industry players are facing. Furthermore, Market Factor Analysis gives insights on how various regulatory, economic factors and policy action are factored in the past and future growth scenarios by various business segments and applications. The Competitive Landscape provides detailed company profiling of players and draws attention on development activities, swot, financial outlook and major business strategic action taken by players.

When it comes to granularity of quantitative data, the market sizing and estimates in dollar term and sales volume are laid from 2015 to 2025 covering major geographic regions of your interest further broken down by product type and by end use application.

Table of Content Global Novel Cell Sorting and Separation Market Research Report

Chapter 1: Novel Cell Sorting and Separation Market Overview

Chapter 2: Global Economic Impact on Industry (COVID Impact Analysis, Local Reforms etc)

Chapter 3: Global Market Competition by Manufacturers

Chapter 4: Global Revenue (Value) , Supplies (Production), Consumption, Export, Import by Regions (2014-2025)

Chapter 5: Global Revenue (Value), volume, Price Trend by Type (2014-2025)

Chapter 7: Global Market Analysis by Application (2014-2025)

Chapter 8: Manufacturing Cost Analysis, Benchmarking (2019)

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

.

What benefits does AMA research studies provides?

Buy full version of this report @ https://www.advancemarketanalytics.com/buy-now?format=1&report=116923 Contact US : Craig Francis (PR & Marketing Manager) AMA Research & Media LLP Unit No. 429, Parsonage Road Edison, NJ New Jersey USA 08837 Phone: +1 (206) 317 1218[emailprotected]

Connect with us athttps://www.linkedin.com/company/advance-market-analyticshttps://www.facebook.com/AMA-Research-Media-LLP-344722399585916https://twitter.com/amareport

The rest is here:
Novel Cell Sorting and Separation Industry Data Statistics Analysis by 2020-2025 - Eurowire

PhD Student/Technician, Studying the Role of Neuroimmunity in Traumatic Brain injury job with UNIVERSITY OF HELSINKI | 231796 – Times Higher Education…

The Biology of Neuro-Immune interaction, HiLIFE-Neuroscience center at University of Helsinki, has an immediate opening for one PhD student/Technician position studying the role of neuroimmunity in Traumatic Brain Injury (TBI). This is an Academy of Finland, Research Council for Health, funded project.

We are a young, enthusiastic group (P.I. Francesco No, PhD, Academy of Finland fellow), seeking for excellence in neuroscience research. For group details, please see https://www.helsinki.fi/en/hilife-neuroscience-center/research/research-...

We are seeking an outstanding, highly motivated individual to join our team to conduct research activities in the field of neuroimmunity, using well-established and innovative techniques, such as flow cytometry and scRNAseq.

The successful candidate has previous research experience in flow cytometry and cell sorting, and knowledge of molecular techniques, including cloning, bulk RNA sequencing, and Western Blot. Previous experience in conducting/analyzing scRNAseq experiments will be regarded as a merit. The candidate will be expected to carry out experiments analyzing phenotype and transcriptome of T lymphocytes extracted from mouse tissues. The ideal candidate will also have research experience in confocal microscopy. The candidate is expected to be self-driven, to have strong work-capacity and enthusiasm for science, and to have good communication skills. The successful candidate will be involved in master students supervision, scientific reporting, and in further collaborations (national and international).

To be appointed as an early stage researcher, the candidate should be qualified to pursue postgraduate studies: i.e., s/he is required to have completed a suitable higher university degree or an equivalent education abroad, which would qualify the person for similar academic studies. The position of PhD Student imply that the Candidate successfully enrolls to one of the Doctoral Programmes at University of Helsinki.

The official language of the laboratory is English. A fluent English language proficiency is required.

The position is filled for a fixed term of one year, starting on 1.12.2020/as soon as possible or as agreed. The salary of the position is determined in accordance with the salary system of Finnish universities. Trial period of 6 months will be applied.

For further information on the position, please contact: Academy Fellow Francesco No, francesco.noe@helsinki.fi

Application should contain the following appendices:

The application needs to be submitted no later than 30.11.2020 (by 24.00 hours Finnish time).

Please submit your application via the University of Helsinki Recruitment System by clicking the Apply for the position button below. Internal applicants (i.e. current employees of the University of Helsinki) should submit their applications through the SAP HR portal. If you need support with the recruitment system, please contact recruitment@helsinki.fi.

The University of Helsinki is an equal opportunity employer. International applicants are encouraged.

HiLIFE -Neuroscience Center

The Neuroscience Center is an international research unit within Helsinki Institute of Life Science (HiLIFE) of the University of Helsinki, a leading Nordic university with a strong commitment to life science research. The research focus of NC is on translational brain plasticity. We carry out research relevant for the human brain both in health and disease, and during development and aging, by applying versatile approaches and modern technology platforms. NC aims at making fundamental discoveries about brain functions and especially translate research findings into improvements in the treatment, prevention and diagnosis of psychiatric and neurological disorders. The research in NC spans across several scales from stem cell research and molecular neuroscience to systems and cognitive neuroscience in both animal and human models. The research groups of NC conduct research in neuroscience at the highest international level and actively apply the results for the benefit of the society. NC collaborates actively with other units of HiLIFE and faculties of the University of Helsinki, Helsinki University Central Hospital, and Neurocenter Finland.

Helsinki Institute of Life Science

Helsinki Institute of Life Science (HiLIFE) is a new institute established in 2017 that supports high quality life science research across the University campuses and faculties. HiLIFE builds on existing strengths and new recruits and partnerships to create an attractive international environment for researchers to solve grand challenges in health, food, and environment. HiLIFE coordinates research infrastructures in life sciences and provides research-based interdisciplinary training.

University of Helsinki

The University of Helsinki (UH), founded in 1640, is a vibrant scientific community of 40,000 students and researchers. It is one of the leading multidisciplinary research universities and ranks among the top 100 international universities in the world. It is currently investing heavily in life sciences research. UH offers comprehensive services to its employees, including occupational health care and health insurance, sports facilities, and opportunities for professional development.

Due date

30.11.2020 23:59 EET

Excerpt from:
PhD Student/Technician, Studying the Role of Neuroimmunity in Traumatic Brain injury job with UNIVERSITY OF HELSINKI | 231796 - Times Higher Education...

We can’t stand idly by: Vote ‘yes’ on Prop. 14 for stem cell research – The Jewish News of Northern California

At the very heart of our Biblical tradition is this commandment from the Book of Leviticus: You shall not stand idly by the blood of your fellow. (Leviticus 19:16)

If we see our sisters or brothers in danger, our job is simple: Provide that help, come to their aid, do what is in our power to protect them and save them.

In the midst of a global pandemic, we feel the call to protect and promote the health and well-being of others even more urgently. Right now, we hear the call to uphold the ultimate Jewish value of pikuach nefesh (saving a life).

Sometimes, we live out that value in an immediate way. We donate blood today, which can save lives in real time. We provide support for basic needs to ensure that people in our community have enough to eat right now. But if we truly wish to move the needle in the work of pikuach nefesh, we must also provide resources to fund research over many years, even decades, that will, ultimately, yield dramatic results.

To truly make a difference, to be Gods partners in bringing healing to the world, we must not stand idly by in both immediate and long-term ways.

California voters have an opportunity to do just this by voting yes on Proposition 14, which will advance the California Institute of Regenerative Medicines stem cell research to help those who are affected by ailments including heart disease, diabetes, Alzheimers, Parkinsons disease, sickle cell disease, spinal cord injuries, Covid-19, and so many other chronic illnesses and injuries.

Funding for this important and vital medical research helps save lives, and it will provide immediate economic stimulus, as well. Even as it funds long-term strategies to alleviate human suffering, Prop. 14 will create jobs during this challenging time. Recent studiessuggest that Prop. 14 would generate approximately $20 billion in increased economic activity in California, yielding more than 100,000 new jobs at every level. This far surpasses Prop. 14s estimated cost of $5.5 billion in bonds.

Critics of the proposition question the need for such funding on a state level today. They argue that Proposition 71, the initiative that originally created the California Institute of Regenerative Medicine, was passed in 2004 only because President George W. Bush had banned federal funding for stem cell research. Now that federal funding for stem cell research is allowed, the critics charge, its no longer Californias responsibility to fund such research; private and federal funding should be used to continue this important work.

However, relying on federal and private funds is too risky. Many in our country wish to stifle and limit stem cell research on religious grounds. Far more importantly, Jewish law on this matter is unequivocal: stem cell research is not just permitted, but, arguably, required as a matter of pikuach nefesh. Numerous halachic authorities have made this clear. It should, therefore, come as no surprise that some of the most exciting work in stem cell research is currently being done in Israel.

Medical experts agree that stem cell research and therapies will save lives and alleviate human suffering. In fact, it already has. One example is the stem cell work Dr. Donald Kohn at UCLA conducted to cure ADA-SCID bubble baby disease.

This work is too important for us to leave it to chance or to allow it to be cut off or limited.

We see Prop. 14s opportunity to provide such resources for life-saving research as a blessing, the fulfillment of core Jewish values.

Just one chapter before the commandment to not stand idly by, our Torah reminds us that the purpose of mitzvot, the very goal of Judaism, is to enhance life. We are commanded: in the pursuit of My laws and statutes you shall live. (Leviticus 18:5) The Rabbis of the Talmud interpret this verse to mean that the ultimate value, above all else, is life itself.

To be sure, it will take many years to realize the promise of current research. But like the well-known story of Honi, who came upon an old man planting a tree that would not bear fruit for another 70 years, we recognize that our efforts are not for ourselves alone. Just as our ancestors sacrificed so that our lives would be better, we commit ourselves to doing the same for our descendants.

The voices of our sisters and brothers cry out to us: friends and family members with diabetes; co-workers fighting against cancer; loved ones slipping away due to the cruel ravages of Alzheimers.

They call out to us in their pain. They are searching for hope.

We cannot stand idly by. We must generously sacrifice so that they and subsequent generations might live and be well.

There are quite literally lives to be saved. Join us by voting yes on Prop, 14 on Nov. 3.

See more here:
We can't stand idly by: Vote 'yes' on Prop. 14 for stem cell research - The Jewish News of Northern California

Stem Cell Therapy Market Industry Research Report, Growth Trends and Competitive Analysis 2020-2027: Magellan, Medipost Co., Ltd, Osiris Therapeutics,…

The report on Global Stem Cell Therapy Market is a dependable point of reference heralding high accuracy business decisions on the basis of thorough research and observation by seasoned research professionals at CMI Research. The report on global Stem Cell Therapy market evidently highlights the causal factors such as demand analysis, trend examination, and technological milestones besides manufacturing activities that have been systematically touched upon to instigate systematic growth projection.

This CMI Research report on global Stem Cell Therapy market systematically studies and follows noteworthy progresses across growth trends, novel opportunities as well as drivers and restraints that impact growth prognosis.

Free Sample Report + All Related Graphs & Charts @:https://www.coherentmarketinsights.com/insight/request-sample/2848

Which market players and aspiring new entrants may witness seamless entry?

Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Anterogen Co. Ltd., Pharmicell Co., Inc., and Stemedica Cell Technologies, Inc.

Predicting Scope: Global Stem Cell Therapy Market, 2020-2027

Elaborate research proposes global Stem Cell Therapy market is likely to experience an impressive growth through the forecast span, 2020-2027, ticking a robust CAGR of xx% USD. The Stem Cell Therapy market is anticipated to demonstrate a whopping growth with impressive CAGR valuation. The Stem Cell Therapy market is also likely to maintain the growth spurt showing signs of steady recovery.

For appropriate analysis of all the market relevant information as well emerging trends and historical developments in the Stem Cell Therapy market, CMI Research has referred to various primary and secondary research practices and contributing factors.

Regional Overview: Global Stem Cell Therapy Market

The report specifically sheds light upon note-worthy business discretion, popular trends investment probabilities aligning with budding opportunities as well as breakthrough developments in policies and monetary inclination echoing investor preferences in Stem Cell Therapy space.

Competitive Landscape: Global Stem Cell Therapy Market

Further in the report, readers are presented with minute details pertaining to significant company profiles, product development, on pricing, production and vital information on raw material and equipment developments also form crucial report contents in this CMI Research report.

Have Any Query? Ask Our Expert @: https://www.coherentmarketinsights.com/insight/request-customization/2848

Segmentation Based on Stem Cell Therapy Market Types:

By Cell Source:Adult Stem CellsInduced Pluripotent Stem CellsEmbryonic Stem CellsOthersGlobal Stem Cell Therapy Market, By Application:Musculoskeletal DisordersWounds and InjuriesCancerAutoimmune disordersOthers

Global Stem Cell Therapy Market Size & Share, By Regions and Countries/Sub-regions:

Asia Pacific: China, Japan, India, and Rest of Asia Pacific

Europe: Germany, the UK, France, and Rest of Europe

North America: the US, Mexico, and Canada

Latin America: Brazil and Rest of Latin America

Middle East & Africa: GCC Countries and Rest of Middle East & Africa

The regional analysis segment is a highly comprehensive part of the report on the global Stem Cell Therapy market. This section offers information on the sales growth in these regions on a country-level Stem Cell Therapy market.

The historical and forecast information provided in the report span between2020 and 2027. The report provides detailed volume analysis and region-wise market size analysis of the market.

Report Investment, a Priority: Explains CMI Research

This report also helps market participants to organize R&D activities aligning with exact market requirements

The report resonates critical findings on decisive factors such as downstream needs and requirement specifications as well as upstream product and service development

The report aids in reader comprehension of the market based on dual parameters of value and volume.

This CMI Research initiated research output on Stem Cell Therapy market is a ready-to-refer handbook of noteworthy cues for easy adoption by market players and stakeholders

CMI Research skillfully underpins a vivid segment analysis of the global Stem Cell Therapy market, rendering appropriate inputs about the revenue generation capabilities of each segment.

Buy this research report @: https://www.coherentmarketinsights.com/insight/buy-now/2848

Thanks for reading our report. If you have any further questions, please contact us. Our team will provide you with the report tailored to your needs.

About Us:

Coherent Market Insightsis a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts Us: +1-206-701-6702 Email:[emailprotected] Web:https://www.coherentmarketinsights.com/

See more here:
Stem Cell Therapy Market Industry Research Report, Growth Trends and Competitive Analysis 2020-2027: Magellan, Medipost Co., Ltd, Osiris Therapeutics,...